Cargando…

The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers

The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[(18)F] fluoroethyl-)-L-tyrosine ((18)F-FET) h...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoblar Vidmar, Marija, Doma, Andrej, Smrdel, Uroš, Zevnik, Katarina, Studen, Andrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224265/
https://www.ncbi.nlm.nih.gov/pubmed/35743228
http://dx.doi.org/10.3390/ijms23126787
Descripción
Sumario:The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[(18)F] fluoroethyl-)-L-tyrosine ((18)F-FET) has been shown to be a useful tool for detecting TRC and TP. We assessed the diagnostic performance of different (18)F-FET PET segmentation approaches and different imaging biomarkers for differentiation between late TRC and TP in glioma patients. Isocitrate dehydrogenase (IDH) status was evaluated as a predictor of disease outcome. In our study, the proportion of TRC in IDH wild type (IDHwt) and IDH mutant (IDHm) subgroups was without significant difference. We found that the diagnostic value of static and dynamic biomarkers of (18)F-FET PET for discrimination between TRC and TP depends on the IDH mutation status of the tumor. Dynamic (18)F-FET PET acquisition proved helpful in the IDH wild type (IDHwt) subgroup, as opposed to the IDH mutant (IDHm) subgroup, providing an early indication to discontinue dynamic imaging in the IDHm subgroup.